Patents by Inventor Cecile Bauche

Cecile Bauche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vectors for molecule delivery to CD11b expressing cells
    Patent number: 10004794
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 26, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1
    Patent number: 9987351
    Abstract: The present invention relates to compositions, methods, and uses employing lentiviral vector particles for induction of an immune response by administration to a human, wherein the lentiviral vector particles comprise a lentiviral vector, wherein the DNA of the lentiviral vector comprises a promoter directing expression of a HTLV-1 p12p30-Tax-HBZ fusion protein. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: June 5, 2018
    Assignee: THERAVECTYS
    Inventors: Deborah Revaud, Cecile Bauche
  • Use of non-subtype B gag proteins for lentiviral packaging
    Patent number: 9752160
    Abstract: The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: September 5, 2017
    Assignees: THERAVECTYS, INSTITUT PASTEUR
    Inventors: Thi-Lan Tran, Pierre Charneau, Cecile Bauche
  • Lentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence
    Patent number: 9657311
    Abstract: The present invention relates to the insertion of an MHC class I, MHC Class II, or ?2 microglobulin upstream promoter sequence into a lentiviral vector to increase viral titers. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: May 23, 2017
    Assignee: THERAVECTYS
    Inventors: Cecile Bauche, Emeline Sarry
  • Lyophilized Lentiviral Vector Particles, Compositions and Methods
    Publication number: 20170037430
    Abstract: Methods of making lyophilized lentiviral vector particles are provided. Compositions comprising lyophilized lentiviral vector particles are also provided. Methods of administering a lentiviral vector particle to a subject and uses of lentiviral vector particle compositions are also provided.
    Type: Application
    Filed: December 22, 2014
    Publication date: February 9, 2017
    Inventors: Cecile Bauche, Gael Ouengue Mbele
  • VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
    Publication number: 20160375119
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 29, 2016
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • LENTIVIRAL VECTORS FOR GENERATING IMMUNE RESPONSES AGAINST HUMAN T LYMPHOTROPHIC VIRUS TYPE 1
    Publication number: 20160331831
    Abstract: The present invention relates to compositions, methods, and uses employing lentiviral vector particles for induction of an immune response by administration to a human, wherein the lentiviral vector particles comprise a lentiviral vector, wherein the DNA of the lentiviral vector comprises a promoter directing expression of an HTLV-1 Tax and/or HBZ antigen, and/or a p12I and/or p30II antigen. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
    Type: Application
    Filed: January 27, 2015
    Publication date: November 17, 2016
    Inventors: Deborah Revaud, Cecile Bauche
  • Vectors for molecule delivery to CD11b expressing cells
    Patent number: 9370564
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: June 21, 2016
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • GLYCOPROTEINS FOR PSEUDOTYPING LENTIVECTORS
    Publication number: 20150182617
    Abstract: The invention relates to compositions and methods based on the use of viral G proteins to pseudotype vectors. The viral G proteins can be expressed by expression vectors and can be used to pseudotype lentiviral vectors. The viral G proteins can be included in a combination of compounds for sequential administration to a mammalian host.
    Type: Application
    Filed: July 25, 2013
    Publication date: July 2, 2015
    Applicant: THERAVECTYS
    Inventors: Cecile Bauche, Emeline Sarry, Lucie Casaban
  • Lentiviral vectors containing an MHC class I promoter
    Patent number: 8951535
    Abstract: The present invention relates to the insertion of a promoter sequence from an MHC class I gene promoter into a lentiviral vector in order to direct the transcription of a transgene, which preferably encodes an immunogenic polypeptide to be expressed in a mammalian cell host, preferably APC (DCs). The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: February 10, 2015
    Assignee: Theravectys
    Inventors: Cecile Bauche, Emeline Sarry
  • USE OF NON-SUBTYPE B GAG PROTEINS FOR LENTIVIRAL PACKAGING
    Publication number: 20140234908
    Abstract: The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.
    Type: Application
    Filed: September 25, 2012
    Publication date: August 21, 2014
    Inventors: Thi-Lan Tran, Pierre Charneau, Cecile Bauche
  • RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS
    Publication number: 20140227323
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: October 25, 2013
    Publication date: August 14, 2014
    Applicants: Ludwig Institute for Cancer, Institut Pasteur
    Inventors: Gilles DADAGLIO, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecil Bauche
  • RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS
    Publication number: 20100310594
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: March 25, 2010
    Publication date: December 9, 2010
    Applicants: Institut Pasteur, a corporation of France, Ludwig Institute for Cancer, a corporation of New York
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
  • Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
    Publication number: 20090117143
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: September 12, 2008
    Publication date: May 7, 2009
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
  • Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
    Publication number: 20070026022
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: May 19, 2006
    Publication date: February 1, 2007
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Eynde, Sandra Morel, Cecile Bauche
  • Modified bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
    Publication number: 20060159697
    Abstract: The invention relates to modified Bordetella adenylate cyclase toxins which are deficient for CD11b/CD18 binding and to their use in the preparation of pharmaceutical composition for the treatment of whooping cough and/or for the protection against Bordetella infection. The invention also relates to specific fragments of Bordetella adenylate cyclase comprising the CD11b/CD18 interaction domain and their use, especially for targeting a molecule of interest to CD11b expressing cells.
    Type: Application
    Filed: December 16, 2005
    Publication date: July 20, 2006
    Inventors: Claude Leclerc, Mohammed El-Idrissi, Daniel Ladant, Cecile Bauche, Peter Sebo, Jirina Loucka, Radim Osicka
  • Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
    Publication number: 20050271679
    Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
    Type: Application
    Filed: November 22, 2004
    Publication date: December 8, 2005
    Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
  • Vectors for molecule delivery to CD11b expressing cells
    Publication number: 20050238637
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions, and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: April 5, 2005
    Publication date: October 27, 2005
    Applicants: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Claude Leclerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
  • Vectors for molecule delivery to CD11b expressing cells
    Publication number: 20040001867
    Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 1, 2004
    Inventors: Claude Leclerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi